- Home
- GILD vs AMGN Comparison
GILD vs AMGN Comparison
Compare GILD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- AMGN
- Stock Information
- Founded
- GILD 1987
- AMGN 1980
- Country
- GILD United States
- AMGN United States
- Employees
- GILD N/A
- AMGN N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GILD Health Care
- AMGN Health Care
- Exchange
- GILD Nasdaq
- AMGN Nasdaq
- Market Cap
- GILD 133.3B
- AMGN 155.9B
- IPO Year
- GILD 1992
- AMGN N/A
- Fundamental
- Price
- GILD $111.73
- AMGN $291.02
- Analyst Decision
- GILD Buy
- AMGN Hold
- Analyst Count
- GILD 25
- AMGN 20
- Target Price
- GILD $110.17
- AMGN $322.30
- AVG Volume (30 Days)
- GILD 8.9M
- AMGN 2.8M
- Earning Date
- GILD 08-07-2025
- AMGN 08-05-2025
- Dividend Yield
- GILD 2.83%
- AMGN 3.28%
- EPS Growth
- GILD 1118.07
- AMGN 56.16
- EPS
- GILD 4.73
- AMGN 10.94
- Revenue
- GILD $28,735,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- GILD $1.59
- AMGN $7.73
- Revenue Next Year
- GILD $3.67
- AMGN $1.68
- P/E Ratio
- GILD $23.62
- AMGN $26.55
- Revenue Growth
- GILD 4.68
- AMGN 15.56
- 52 Week Low
- GILD $66.01
- AMGN $253.30
- 52 Week High
- GILD $119.96
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- GILD 58.05
- AMGN 47.27
- Support Level
- GILD $104.46
- AMGN $275.70
- Resistance Level
- GILD $112.00
- AMGN $286.17
- Average True Range (ATR)
- GILD 2.78
- AMGN 7.03
- MACD
- GILD 0.05
- AMGN -1.35
- Stochastic Oscillator
- GILD 89.70
- AMGN 42.16
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.